Find Clinical Trial

The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year. – MALEO


← Back
Study Phase

Phase 3

Therapeutic Area

Rheumatology

IndicationOsteoporosis
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

STRONTIUM RANELATE,
S012911

Active Substance CodeS012911
Protocol CodeCL3-12911-032
EudraCT Code2006-006086-16
ISRCTN CodeISRCTN49960746


Documents and links

First results summary READ MORE
Second results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility